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cell adhesion molecule-1 (VCAM-1), alpha-1 acid glycoprotein
(AGP) and C-reactive Protein (CPR) for two homozygous sickle
cell patients, and it’s association with clinical episodes, hemoglobin
S% determination and donor cell percentages. We report two
patients with Sickle cell disease (SCD) had multiple Cerebro-
Vascular-Accident (CVA) and recurrent vasco-occulsive crises and
failed to respond to chronic transfusion program with Desferal
rescue, underwent HLA-matched Allogenic Bone Marrow Trans-
plantation (BMT). Patients were prepared for transplantation us-
ing standard regimen which comprised Busulfan (BU) 3.5 mg/kg
PO every 6H for total of 16 doses, four days of Cytoxan (50 mg/kg)
and, ATG (30mg/kg) for 3days. Both were given antiseizure pro-
phylaxis from day-2 to day 14 and continued with cyclosporin
(1.5 mg/kg) for 6 months post-transplant and because of poor renal
function patient #1 received methylprednisone 1mg/kg as alterna-
tive to methetotrexate while patient #2 received standard short
course of methetrexate for GVHD prophylaxis. Neutrophil En-
graftment (0.5 109/L) occurred in day10, day14 respectively
with augmentation of GCSF. Both had stable clinical and cytogen-
tic engraftment. Post BMT complication were signiﬁcant for SVS
(superior vena cava syndrome) which completely resolved with r
TPA for patient #1 and chronic cutenous GVHD for patient #2
which managed with steroid. Pre BMT adhesion molecules
VCAM-1, AGP and plasma factor CRP were determined and
correlated with clinical episodes of crises, Hgb S% and donor cell
percentage. VCAM-1 level was 1041 ng/ml, AGP 1.14 mg/L, and
CRP 11.64 mg/L on day –4 for patient #1 which declined by 38%
on day 16 for VCAM-1 16%, and 100% for AGP and CRP
respectively. While VCAM-1 level was 3404 ng/ml, AGP 1.14
mg/L, and CRP 11.64 mg/L for patient #2 on day-2, these were
noticed to decline gradually and reach minimum of 970 ng/ml
(down by 71%) of VCAM-1, 1.0 mg/L of AGP (12%), and almost
100% decrease of CRP. Our results suggest the role of Stem cell
allograft in reversing the progression of vasculopathy through
decreasing adherence and interaction of both red cell, endothelial
cell and plasma factors.
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THE USE OF FLUDARABINE BASED REDUCED INTENSITY CONDITION-
ING FOR THE TREATMENT OF PATIENTS WITH FANCONI’S ANEMIA
Slavin, S., Bitan, M., Aker, M., Resnik, I., Shapira, M.Y., Or, R.
Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Allogeneic stem cell transplantation (SCT) is the only curative
modality for Fanconi’s anemia (FA). FA patients are most susceptible
to alkylating agents and radiation at dose ranges commonly used in
preparation for SCT. For FA, ﬂudarabine based non-myeloablative
stem cell transplantation (NST) is particularly attractive for reducing
toxicity and improving immediate and long-term outcome following
SCT. Sixteen FA patients were transplanted in our center between
1989-2002. Eight patients were transplanted with cyclophosphamide
and ionizing irradiation (total lymphoid irradiation) (CY-TLI). Six
patients were treated, with NST consisting of ﬂudarabine 30mg/
meter sq/day  6; cyclophosphamide 5mg/kg/day 2 and rabbit
anti-T lymphocyte globulin (ATG) 10mg/kg 4. Higher dose of
cyclophosphamide of 10mg/kg/day 2 was used in a patient with
leukemic transformation with thrombocytopenia and 20% myelo-
blasts. The regimen was well tolerated with no transplant related
toxicity or any major complication. However, rejection was observed
when the protocol was applied for a matched unrelated donor
(MUD). A second transplant from another unrelated donor was suc-
cessfully accomplished without complications using a combination of
ﬂudarabine, busulfan 4mg/kg/day 2 and Campath-1H (humanized
anti-CD52), and therefore, it was decided that this protocol will also
be used for a subsequent case. All 8/8 patients treated with NST with
stem cells obtained from a matched sibling or MUD survive, follow-
ing uneventful SCT procedure with 100% donor cell chimerism, fully
reconstituted with no severe acute or chronic GVHD, whereas in the
CY-TLI group 50% are currently alive post transplantation. More-
over, looking at several parameters associated with post-transplant
complications, like fever, infections, the need for total parental nutri-
tion, veno-occlusive disease of the liver and graft-versus-host disease,
NST protocol appears superior according to all parameters. Based on
our data, ﬂudarabine based NST may represent the treatment of
choice for patients with FA with a matched sibling or MUD available.
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REDUCED INTENSITY (RI) CONDITIONING AND ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) IN PEDIATRIC PA-
TIENTS WITH NON-MALIGNANT DISORDERS
Jacobsohn, D.A., Kletzel, M., Duerst, R. Children’s Memorial Hospital,
Chicago, IL
Because children tolerate intensive regimens with less TRM,
there has been reluctance to use RI regimens in them despite
potential beneﬁt for reduced long-term morbidity. RI regimens are
of interest in children with nonmalignant disorders since there’s no
obvious need for high-dose therapy or GVL. Of 30 pts who
underwent RI HSCT at Children’s Memorial Hospital, 12 (6M,
6F) had nonmalignant disorders. Diagnoses: 5 immunodeﬁciencies
(2 Hyper-IgM, 1 Omenn’s, 1 X-linked lymphoproliferative dis-
ease, 1 chronic granulomatous disease), 3 metabolic disorders (1
Hurler’s, 1 mucolipidosis II/III, 1 Sandhoff), 4 hemoglobinopa-
thies (3 sickle cell, 1 beta-thalassemia). Median age: 6 yrs (range
0.5-22.5). Stem cell sources: PBSC from 6 unrelated donors, 4
matched siblings, 1 mismatched parent, and 1 unrelated cord
blood. Regimen: ﬂudarabine 30 mg/m2 (day (d) –10 to –5), IV
busulfan, 0.8-1 mg/kg8 doses or 3.2 mg/kg 2 doses (d –5 and
–4), and equine ATG 40 mg/kg or rabbit ATG 2 mg/kg (d –4 to
–1). GVHD prophylaxis: CsA (7), CsA/MMF (5). Median time to
ANC 500/ul  19 d (10-61), and to unsupported platelet
count  20,000/ul  16.5 d (10-61). Median time to full donor
chimerism (VNTR 95-100%)  143 d (14-473) in 8 of 11 evalu-
able pts (1 hyper-IgM pt remains a mixed chimera, 2 with hemo-
globinopathies never developed donor chimerism). One hemoglo-
binopathy pt achieved full donor chimerism but rejected at 2 yrs
(after PBSC boost). Post-HSCT PBSC boosts were given to 5 pts
for falling donor chimerism. One pt developed aGVHD II-IV; 3 of
8 surviving past d100 with donor chimerism developed limited (2)
or extensive (1) cGVHD. Median survival is 609 d (7-1251). Of 12
pts, 8 are alive. 100d TRM occurred in 2 (measles encephalitis in
1, ARDS in Omenn’s pt who began conditioning with active
infection/ARDS and died d7). Six of the survivors continue to
show donor chimerism. The 2 survivors with autologous recovery
are hemoglobinopathy pts. Whereas 1 of 4 hemoglobinopathy pts
had sustained engraftment, 7 of the 7 remaining evaluable pts have
stable engraftment. Immunodeﬁciency pts had obvious clinical
beneﬁt from HSCT but more time is needed to assess impact of RI
HSCT in pts with metabolic disorders. In children with nonma-
lignant disorders other than hemoglobinopathies, this RI regimen
is relatively non-toxic and promotes engraftment, even with unre-
lated donors. However, in children with hemoglobinopathies, this
RI regimen is associated with non-engraftment or late graft rejec-
tion and should not be performed.
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A TEST DOSE OF I.V. BUSULFAN (BU) IS PREDICTIVE OF THE AREA
UNDER THE CURVE (AUC) OF A SINGLE DAILY DOSE OF I.V. BU IN
PEDIATRIC PATIENTS UNDERGOING A REDUCED INTENSITY (RI) HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Kletzel, M., Jacobsohn, D., Duerst, R. Northwestern University Child-
rens Memorial Hospital, Chicago, IL
High-dose BU-containing chemotherapy has been used in autol-
ogous and allogeneic HSCT. Variations in the PK for oral BU in
pediatric patients have resulted in either decreased effect or in-
creased toxicity. The IV formulation eliminates the variability of
Table.
VCAM
ng/mL
(#1)
AGP
mg/L
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CRP
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VCAM
ng/mL
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AGP
mg/L
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CRP
mg/L
(#2)
Post BMT 871 0.948 0 970 1.0 0
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